Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 2/20 | 0.43 |
| ▸ | SKP1 | P63208 | 2/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5698822 | 0.86 | IDE (0.40) | MAPK1SMN1; SMN2MAPTTP53POLB | |
| SCHEMBL4800390 | 0.82 | MAPT (0.45) | MAPK1MAPTCKS1BSKP1SKP2 | |
| SCHEMBL2854558 | 0.80 | HRH1 (0.47) | ACHECKS1BSKP1SKP2GPR119 | |
| SCHEMBL520241 | 0.79 | MAP4K4 (0.50) | SMN1; SMN2MAPTACHEADORA2ACKS1B | |
| SCHEMBL520960 | 0.79 | CKS1B (0.49) | SMN1; SMN2MAPTACHECKS1BSKP1 | |
| SCHEMBL4799911 | 0.78 | HTR6 (0.53) | — | |
| Hydrochloric Acid SCHEMBL4802553 | 0.77 | HTR6 (0.52) | — | |
| SCHEMBL6284838 | 0.76 | CKS1B (0.52) | MAPK1SMN1; SMN2MAPTACHEADORA2A | |
| SCHEMBL4800091 | 0.76 | CKS1B (0.51) | MAPTACHECKS1BSKP1SKP2 | |
| SCHEMBL1048457 | 0.75 | POLB (0.55) | MAPTACHECKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439243-B2 | Piperazinyl-quinoline derivatives useful for the treatment of CNS disorders | GLAXO GROUP LIMITED (GB) | 2008-10-21 | — | — | US | disclosed |
| EP-1663981-B1 | PIPERAZINYL-QUINOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2007-07-18 | — | — | EP | disclosed |
| US-20070027139-A1 | Piperazinyl-quinoline derivatives useful for the treatment of cns disorders | GLAXO GROUP LIMITED (GB) | 2007-02-01 | — | — | US | disclosed |
| EP-1663981-A1 | PIPERAZINYL-QUINOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030724-A1 | PIPERAZINYL-QUINOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027139-A1 | Piperazinyl-quinoline derivatives useful for the treatment of cns disorders | PMP22, AQP4, GRIN2A | MAPK1 3207/4885SMN1; SMN2 150/4885MAPT 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.